Institution
University at Buffalo
Education•Buffalo, New York, United States•
About: University at Buffalo is a education organization based out in Buffalo, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 33773 authors who have published 63840 publications receiving 2278954 citations. The organization is also known as: UB & State University of New York at Buffalo.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: An association between neocortical volume and multiple cognitive domains in MS is confirmed, although neocorticals volume did not explain significantly more variance than other magnetic resonance imaging measures.
Abstract: Results: Patients with secondary progressive MS had more atrophy than patients with relapsing-remitting MS and controls Neocortical volume was significantly correlated with all neuropsychological measures, withr values ranging from 029 to 058 Third ventricular width was retained in most stepwise regression analyses predicting cognitive impairment in patients with MS and distinguishing secondary progressive from relapsingremitting courses of MS Conclusions: We confirm an association between neocortical volume and multiple cognitive domains in MS, although neocortical volume did not explain significantly more variance than other magnetic resonance imaging measures Of the magnetic resonance imaging variables studied, third ventricular width was retained in most regression models
300 citations
••
TL;DR: A methodology for ontology development that is now being used by multiple groups of researchers in different life science domains is tested and refined, and some of its principles are being applied, especially within the framework of the OBO (Open Biomedical Ontologies) Foundry initiative.
Abstract: Since 2002 we have been testing and refining a methodology for ontology development that is now being used by multiple groups of researchers in different life science domains. Gary Merrill, in a recent paper in this journal, describes some of the reasons why this methodology has been found attractive by researchers in the biological and biomedical sciences. At the same time he assails the methodology on philosophical grounds, focusing specifically on our recommendation that ontologies developed for scientific purposes should be constructed in such a way that their terms are seen as referring to what we call universals or types in reality. As we show, Merrill's critique is of little relevance to the success of our realist project, since it not only reveals no actual errors in our work but also criticizes views on universals that we do not in fact hold. However, it nonetheless provides us with a valuable opportunity to clarify the realist methodology, and to show how some of its principles are being applied, especially within the framework of the OBO (Open Biomedical Ontologies) Foundry initiative.
300 citations
••
300 citations
••
01 Sep 2016TL;DR: The results show that CNO has multiple dose-dependent effects in vivo and is converted to clozapine and N-Des emphasizing the need for a CNO-only DreadD-free control group when designing DREADD-based experiments.
Abstract: Clozapine N-oxide (CNO) is a ligand for a powerful chemogenetic system that can selectively inhibit or activate neurons; the so-called Designer Receptors Exclusively Activated by Designer Drugs (DREADD) system. This system consists of synthetic G-protein-coupled receptors, which are not believed to be activated by any endogenous ligand, but are activated by the otherwise inert CNO. However, it has previously been shown that the administration of CNO in humans and rats leads to detectable levels of the bioactive compounds clozapine and N-desmethylclozapine (N-Des). As a follow-up, experiments were conducted to investigate the effects of CNO in male Long-Evans rats. It was found that 1 mg/kg CNO reduced the acoustic startle reflex but had no effect on prepulse inhibition (PPI; a measure of sensorimotor gating). CNO (2 and 5 mg/kg) had no effect on the disruption to PPI induced by the NMDA antagonist phencyclidine or the muscarinic antagonist scopolamine. In locomotor studies, CNO alone (at 1, 2, and 5 mg/kg) had no effect on spontaneous locomotion, but 5 mg/kg CNO pretreatment significantly attenuated d-amphetamine-induced hyperlocomotion. In line with the behavioral results, fast-scan cyclic voltammetry found that 5 mg/kg CNO significantly attenuated the d-amphetamine-induced increase in evoked dopamine. However, the effects seen after CNO administration cannot be definitively ascribed to CNO because biologically relevant levels of clozapine and N-Des were found in plasma after CNO injection. Our results show that CNO has multiple dose-dependent effects in vivo and is converted to clozapine and N-Des emphasizing the need for a CNO-only DREADD-free control group when designing DREADD-based experiments.
300 citations
Authors
Showing all 34002 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rakesh K. Jain | 200 | 1467 | 177727 |
Julie E. Buring | 186 | 950 | 132967 |
Anil K. Jain | 183 | 1016 | 192151 |
Donald G. Truhlar | 165 | 1518 | 157965 |
Roger A. Nicoll | 165 | 397 | 84121 |
Bruce L. Miller | 163 | 1153 | 115975 |
David R. Holmes | 161 | 1624 | 114187 |
Suvadeep Bose | 154 | 960 | 129071 |
Ashok Kumar | 151 | 5654 | 164086 |
Philip S. Yu | 148 | 1914 | 107374 |
Hugh A. Sampson | 147 | 816 | 76492 |
Aaron Dominguez | 147 | 1968 | 113224 |
Gregory R Snow | 147 | 1704 | 115677 |
J. S. Keller | 144 | 981 | 98249 |
C. Ronald Kahn | 144 | 525 | 79809 |